US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Psyence Biomedical Ltd

0.4381

-0.0267-5.74%

Post-market: 0.43810.00000.00%18:55 EDT

Volume:156.54K

Turnover:69.00K

Market Cap:1.94M

PE:-0.01

High:0.4770

Open:0.4665

Low:0.4137

Close:0.4648

Loading ...

Overview Company News Filings

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Group Inc - to Consolidate Shares 15 to 1 Effective April 23, 2025

THOMSON REUTERS

CVS Health vs. UnitedHealth: Which Healthcare Stock Has More Upside?

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

CVS Health Takes the Lead in 2025 S&P 500 Chart: Is It a Buy Now?

Jim Cramer on CVS Health (CVS): “A Comeback Story with New Management!”

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

What Gives Elevance Health (ELV) an Attractive Opportunity in The Large Cap Space?

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

UnitedHealth's Optum Rx & EPN Team Up for Fairer Pharmacy Payments

UnitedHealth Group (UNH): The Best Diabetes Stock to Buy According to Billionaires

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

Is CVS Health (CVS) the Best Stock to Buy Right Now?

Psyence Group's Nasdaq-Listed Associate, Psyence Biomedical, Names Albert P. Garcia-Romeu, Ph.d. as Chair of Its Newly Created Scientific Advisory Board

THOMSON REUTERS

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

Is CVS Health Corporation (CVS) the Top Health Insurance Stock to Buy Now?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PBM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PBM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBM\",,,,,undefined,":{"symbol":"PBM","market":"US","secType":"STK","nameCN":"Psyence Biomedical Ltd","latestPrice":0.4381,"timestamp":1744920000000,"preClose":0.4648,"halted":0,"volume":156536,"hourTrading":{"tag":"盘后","latestPrice":0.4381,"preClose":0.4381,"latestTime":"18:55 EDT","volume":38,"amount":17.6398,"timestamp":1744930502627},"delay":0,"floatShares":3309090,"shares":4427128,"eps":-76.91162,"marketStatus":"Closed Good Friday","change":-0.0267,"latestTime":"04-17 16:00:00 EDT","open":0.4665,"high":0.477,"low":0.4137,"amount":69000.50996648001,"amplitude":0.136188,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-76.91162,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.4648,"preHourTrading":{"tag":"盘前","latestPrice":0.477,"preClose":0.4648,"latestTime":"09:20 EDT","volume":410,"amount":195.1569004,"timestamp":1744896040185},"postHourTrading":{"tag":"盘后","latestPrice":0.4381,"preClose":0.4381,"latestTime":"18:55 EDT","volume":38,"amount":17.6398,"timestamp":1744930502627},"volumeRatio":2.480611},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBM\",,,,,undefined,":{"symbol":"PBM","floatShares":3309090,"roa":"-137.78%","roe":"-457.86%","lyrEps":-588.738814,"volumeRatio":2.480611,"shares":4427128,"dividePrice":0,"high":0.477,"amplitude":0.136188,"preClose":0.4648,"low":0.4137,"week52Low":0.3666,"pbRate":"-1.55","week52High":108,"institutionHeld":0.0125,"latestPrice":0.4381,"eps":-76.91162,"divideRate":0,"volume":156536,"delay":0,"ttmEps":-76.91162,"open":0.4665,"prevYearClose":2.11,"prevWeekClose":0.4489,"prevMonthClose":0.6,"prevQuarterClose":0.6,"fiveDayClose":0.4521,"twentyDayClose":0.67,"sixtyDayClose":1.67},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528377728","title":"Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2528377728","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528377728?lang=en_us&edition=fundamental","pubTime":"2025-04-18 07:17","pubTimestamp":1744931820,"startTime":"0","endTime":"0","summary":"New York, New York-- - Psyence Biomedical Ltd.   announced today that it received a notification letter dated April 16, 2025, from the Listings Qualifications Department  of the Nasdaq Stock Market LLC  indicating that the Company is not in compliance with Nasdaq Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share . The Staff's determination is based on the closing bid price of the Company's common shares being below $1.00 for 30 consecutive business days from March 5, 2025 through April 15, 2025.The Company intends to appeal this determination and request a hearing before a Nasdaq Hearings Panel. Under Nasdaq rules, this request will stay the suspension of trading and the delisting of the Company's securities pending the outcome of the hearing and any extension the Hearings Panel provides.Psyence BioMed is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psyence-biomed-receives-nasdaq-notification-231700357.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psyence-biomed-receives-nasdaq-notification-231700357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089279066.USD","LU2092937221.SGD","QID","IE00BGHQF748.EUR","IE00B64PRP62.GBP","QLD","BK4567","NQmain","A","BK4121","IE00BN0W2W23.USD","LU2041044095.USD","LU2413666426.HKD","SQQQ","MNQmain","PSQ","BK4585",".IXIC","BK4139","BK4588","IE00BN0W2T93.GBP","IE00BKPKM429.USD","LU2210150020.SGD","TQQQ","LU0347712357.USD","BK4112","USAW.SI","USJW.SI","IE00B3QW5Z07.USD","LU2095319765.USD","LU1721428933.USD","LU2413666699.HKD","LU2229751404.USD","PBMWW","LU2210149790.SGD","IE00BN0W2V16.EUR","NVIW.SI","LU1165135440.EUR","TSYW.SI","NDAQ","PBM","LU1543694498.USD"],"gpt_icon":1},{"id":"2528074825","title":"Psyence Group Inc - to Consolidate Shares 15 to 1 Effective April 23, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2528074825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528074825?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:39","pubTimestamp":1744897182,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV2YA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2527783584","title":"CVS Health vs. UnitedHealth: Which Healthcare Stock Has More Upside?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527783584","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527783584?lang=en_us&edition=fundamental","pubTime":"2025-04-16 03:00","pubTimestamp":1744743600,"startTime":"0","endTime":"0","summary":"Currently, CVS Health CVS and UnitedHealth Group UNH are two major vertically integrated behemoths in the U.S. healthcare market and key constituents of the S&P 500 index. Both companies have transformed beyond their original identities — CVS Health from a retail pharmacy chain into a healthcare powerhouse through its acquisition of Aetna and UnitedHealth from a traditional insurer into a tech-enabled care provider via its expansive Optum platform. Each now combines insurance, care delivery, pharmacy benefit management  and value-based service models to offer end-to-end healthcare solutions.For investors, it is difficult to choose between the two, as both CVS and UnitedHealth continue to diversify their revenue streams and scale up their clinical and digital infrastructure. While they share structural similarities in business segmentation — insurance, health services, and pharmacy operations — their financial trajectories, operating margins, capital deployment strategies and risk expos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvs-health-vs-unitedhealth-healthcare-190000788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0211326839.USD","LU1934455863.HKD","LU1983299246.USD","LU0158827948.USD","LU0097036916.USD","LU0545039389.USD","LU1720051108.HKD","LU0128525689.USD","LU1261432733.SGD","LU1066053197.SGD","LU0029864427.USD","LU0417517546.SGD","SGXZ57979304.SGD","LU1066051498.USD","LU0353189680.USD","LU0820562030.AUD","LU0316494557.USD","LU0912757837.SGD","LU2023251221.USD","LU2264538146.SGD","PBM","HCSG","BK4581","LU0310799852.SGD","LU0882574055.USD","LU1914381329.SGD","UNH","LU0238689110.USD","LU1119994496.HKD","SG9999014898.SGD","IE0004445015.USD","LU1791710400.SGD","CVS","IE00B19Z3B42.SGD","IE00BJT1NW94.SGD","IE00BZ1G4Q59.USD","LU1084165304.USD","LU0211326755.USD","LU2361045086.USD","LU0820561909.HKD","IE00BZ9MQY76.HKD","LU0708995401.HKD","LU1066051811.HKD","MCR","LU0072461881.USD","BK4533","IE0005OL40V9.USD","IE000M9KFDE8.USD","LU1496350502.SGD","SG9999018857.SGD"],"gpt_icon":1},{"id":"2527416319","title":"Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2527416319","media":"Newsfile","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527416319?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:30","pubTimestamp":1744720200,"startTime":"0","endTime":"0","summary":"New York, New York-- - Psyence Biomedical Ltd.   today announced a strategic follow-on investment of USD $500,000 into PsyLabs, a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients  and extracts for research, clinical trials, and drug development. This follow-on investment underscores Psyence BioMed's commitment to building a vertically integrated, multi-asset psychedelics biotech platform with robust supply chain security and clinical development capabilities.This new capital investment builds on the exclusive, royalty-bearing IP licensing agreement formalized between the two companies in September 2024, following an initial investment where Psyence BioMed acquired an 11.13% equity stake in PsyLabs. Under the terms of that agreement, PsyLabs supplies Psyence BioMed with pharmaceutical-grade, EU-GMP, nature-derived  psilocybin for use in future clinical trials and eventual commercialization in substance use disorders .Tony Budden, Chi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psyence-biomed-announces-usd-500-123000986.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psyence-biomed-announces-usd-500-123000986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4503","BK4535","BK4551","BK4023","PBM","PBMWW","USD","BK4139","API"],"gpt_icon":0},{"id":"2525899338","title":"Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2525899338","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525899338?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"New partnership strengthens Psyence BioMed's global clinical trial capabilities, accelerating the development of psilocybin-assisted therapy for adjustment disorder. New York, New York-- - Psyence BioMed   today announced the signing of a Letter of Intent  with Southern Star Research Pty Ltd, a premier Australian contract research organization . This collaboration will accelerate Psyence BioMed's ongoing Phase IIb psilocybin clinical trial in Australia, which focuses on adjustment disorder in patients diagnosed with cancer.Adjustment disorder ranks as the seventh most frequently diagnosed psychiatric condition globally, affecting millions of people who currently have no FDA-approved pharmaceutical treatment.Psyence BioMed senior leadership will discuss the new agreement during the Company's corporate webinar on Thursday, April 10, 2025, at 12:00 PM EST.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psyence-biomed-signs-loi-southern-120000514.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psyence-biomed-signs-loi-southern-120000514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1621767737.EUR","LU1718418525.SGD","LU1162221912.USD","LU1621767810.EUR","LU1621768206.USD","BK4139","PBM","LU2133065610.SGD","BK4081","IE00BMG7P926.USD","IE00BMG7P587.USD","IE00B29SXK94.USD","LU0320765646.SGD","PBMWW","LU0310799852.SGD","IE00BMG7P819.SGD","LU2384288077.EUR","BK4585","LU1267930490.SGD","LU0211327993.USD","LU1929549753.HKD","SO","BK4588","IE00B29SXL02.USD","LU1621768115.EUR","LU0211328371.USD","IE00BMG7P694.USD"],"gpt_icon":0},{"id":"2525767690","title":"CVS Health Takes the Lead in 2025 S&P 500 Chart: Is It a Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2525767690","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525767690?lang=en_us&edition=fundamental","pubTime":"2025-04-08 03:00","pubTimestamp":1744052400,"startTime":"0","endTime":"0","summary":"In a year marked by macroeconomic uncertainty and renewed trade tensions that have shaken the equity market, CVS Health CVS has emerged as an unexpected outperformer. After a rough 2024, marked by high utilization at its Aetna insurance unit as well as reimbursement pressure, CVS Health has experienced a dramatic recovery so far in 2025. The stock has become the S&P 500’s top performer, with a year-to-date return exceeding 41%, thereby outperforming all other index members by a significant margin.This PBM and pharmacy retail powerhouse has also outperformed its major competitors — Herbalife Ltd. HLF and Walgreens Boots WBA, which registered growth of 23.6% and 14.6%, respectively, during this period.CVS Health is optimistic regarding its path forward in 2025 and beyond, which involves strengthening its positioning in Medicare Advantage. Management is confident about 2025 pricing, which is based on prudent assumptions for utilization trends. It expects these actions to drive a 100- to 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvs-health-takes-lead-2025-190000258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0211331839.USD","SPY","HLF","SDS","OEF","LU0162691827.USD","ESmain","LU0006061336.USD","BK4588",".SPX","WBA","BK4532","BK4581","IE00B19Z3B42.SGD","BK4183","BK4128","LU0321505868.SGD","IE00B19Z3581.USD","CVS","BK4504","LU1699723380.USD","LU2211815571.USD","IE00BZ1G4Q59.USD","SH","LU1571399168.USD","LU0208291251.USD","LU0072461881.USD","LU2264538146.SGD","IE00B19Z4B17.USD","LU2249611893.SGD","IE0002270589.USD","GTLS","LU1059921491.USD","BK4196","BK4534","IE00B7SZL793.SGD","IE00BKVL7J92.USD","PBM","VOO","OEX","BK4550","LU1064131342.USD","BK4161","LU0061475181.USD","LU0823414478.USD","LU0320765489.SGD","IVV","SSO"],"gpt_icon":1},{"id":"2523929927","title":"Jim Cramer on CVS Health (CVS): “A Comeback Story with New Management!”","url":"https://stock-news.laohu8.com/highlight/detail?id=2523929927","media":"Insider Monkey","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523929927?lang=en_us&edition=fundamental","pubTime":"2025-03-31 23:13","pubTimestamp":1743434027,"startTime":"0","endTime":"0","summary":"We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look at where CVS Health Corporation’s  stands against other stocks that Jim Cramer looked at recently.Jim Cramer, the host of Mad Money, offered an optimistic perspective on the market on Thursday as he challenged the prevailing pessimism among some on Wall Street. He highlighted the diverse range of sectors showing gains.READ ALSOJim Cramer Put These 16 Stocks Under a MicroscopeandJim Cramer Commented on These 8 Stocks Recently. Cramer observed that when investors are focused on long-standing winners, like tech stocks, it can be easy to miss when their dominance starts to wane. Cramer expressed his hesitation to part ways with tech given its long-term success but he pointed out something surprising as he reviewed the top-performing sectors.Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperfor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-cvs-health-cvs-151347661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0353189763.USD","LU0345769631.USD","LU1119994496.HKD","LU2361044865.SGD","IE0004086264.USD","LU0345769128.USD","LU0070302665.USD","LU0096362180.USD","PBM","BK4227","IE00BHPRN162.USD","LU0056508442.USD","LU0061474705.USD","LU2417539215.USD","LU0823434740.USD","LU0170899867.USD","LU0823434583.USD","BK4581","LU0889565833.HKD","BK4196","LU1267930730.SGD","MA","LU2543165471.USD","LU0868494617.USD","CVS","LU1571399168.USD","LU1852331112.SGD","LU0276348264.USD","LU2106854487.HKD","LU0127658192.USD","LU2461242641.AUD","SGXZ99366536.SGD","LU0238689110.USD","LU0557290698.USD","LU0390134368.USD","LU0345770993.USD","IE00BQXX3F31.USD","LU2361045086.USD","IE00B1XK9C88.USD","BK4527","LU1366192091.USD","IE00BKVL7J92.USD","IE00BQXX3C00.GBP","LU0640476718.USD","LU0109391861.USD","LU2764262908.HKD","IE00BQXX3D17.EUR","LU2361044949.HKD","IE00BFSS8Q28.SGD","GB00BDT5M118.USD"],"gpt_icon":1},{"id":"2523794994","title":"Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2523794994","media":"Newsfile","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523794994?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025. New York, New York-- - Psyence Biomedical Ltd.   releases the following update:. At Psyence BioMed, we are truly grateful for the ongoing support and trust of our shareholders. Your dedication to our vision drives our growth, and we're excited to share our latest global achievements. We are committed to keeping you well-informed and engaged. As we embrace the exciting opportunities in the psychedelics industry, we look forward to continuing this conversation together.Our exclusive royalty-bearing IP licensing agreement with Psyence UK Group Ltd. , an international psychedelic Active Pharmaceutical Ingredient  development company with a facility that is federally licensed to cultivate and export psychedelic compounds to the legal medical and research markets, may support long-term access to EU-GMP certified ingredients. This partnership strengthens our position in the growing psy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/corporate-psyence-biomedical-ltd-redefines-120000215.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corporate-psyence-biomedical-ltd-redefines-120000215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["API","STRK","BK4595","BK4516","BK4139","BK4551","BK4596","PBMWW","BK4585","BK4503","BK4535","BK4600","PBM","BK4588","BK4023"],"gpt_icon":1},{"id":"2522957488","title":"What Gives Elevance Health (ELV) an Attractive Opportunity in The Large Cap Space?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522957488","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522957488?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:57","pubTimestamp":1743166645,"startTime":"0","endTime":"0","summary":"River Road Asset Management, an investment management company released its “River Road Large Cap Value Select Fund” Q4 2024 investor letter. A copy of the letter can be downloaded here. In the fourth quarter, AMG River Road Large Cap Value Select Fund returned 0.43% compared to  return for the Russell 1000 Value Index. For the year 2024, the fund returned 24.59% significantly outperforming Index return of 14.37%. Stocks rallied in November after a Republican victory but declined sharply following hawkish Fed comments. Shorter duration stocks, including small caps and value, lost most of their post-election gains by the end of December. For more information on the fund’s best picks in 2024, please check its top five holdings.River Road Large Cap Value Select Fund stated the following regarding Elevance Health, Inc.  in its Q4 2024 investor letter:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gives-elevance-health-elv-attractive-125725904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ELV","LU1506573853.SGD","LU1815333072.USD","LU2237957902.USD","BK4139","LU0070302665.USD","PBM","SG9999004303.SGD","LU1489326972.SGD","LU1670628061.USD","LU2362541513.USD","LU1057294990.SGD","LU0882574055.USD","LU0061474960.USD","LU2362540622.SGD","LU0225283273.USD","SGXZ23171101.USD","BK4154","LU0068578508.USD","LU0122379950.USD","LU2108987350.USD","LU2357305700.SGD","LU0006306889.USD","LU1720051108.HKD","LU1548497426.USD","LU1670627923.USD","LU0251131958.USD","LU0211331839.USD","LU1280957306.USD","LU0433182093.SGD","LU2244417387.USD","LU0058720904.USD","LU0557290698.USD","LU0985489474.SGD","LU0048573561.USD","SG9999001077.SGD","LU1983299246.USD","LU0187121727.USD","LU0266013472.USD","SG9999011175.SGD","LU2430703251.USD","LU1023059063.AUD","LU0320765489.SGD","LU0208291251.USD","LU0640476718.USD","BK4588","LU2430703178.SGD","LU0114720955.EUR","LU2505996681.GBP","LU0878866978.SGD"],"gpt_icon":0},{"id":"2522006189","title":"Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein","url":"https://stock-news.laohu8.com/highlight/detail?id=2522006189","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522006189?lang=en_us&edition=fundamental","pubTime":"2025-03-25 22:47","pubTimestamp":1742914020,"startTime":"0","endTime":"0","summary":"According to a news release issued by PBM, Dr. Stein is the Professor and Chair of the Dept of Psychiatry and Mental Health at the University of Cape Town  and Director of the South African Medical Research Council  Unit on Risk & Resilience in Mental Disorders. Dr. Stein will work closely with SAB chairman, Albert P. Garcia-Romeu, Ph.D, an Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine. The PBM news release goes on to state that in addition to the continuation of PBM's Phase IIb clinical trial of psilocybin as a potential treatment for Adjustment Disorder in Palliative Care, PBM will also be advancing plans for its second development indication in Alcohol Use Disorder, introducing an entirely new class of psilocybin-based therapeutics to address significant unmet needs in mental health and addiction.To register for the corporate webinar, please access the following link: Psyence Biomed Corporate Webinar. Informe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psyence-groups-nasdaq-listed-associate-144700681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","BK4139","USJW.SI","BK4588","LU2095319765.USD","BK4112","TSYW.SI","MNQmain","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR",".IXIC","LU2210150020.SGD","PBMWW","IE00B64PRP62.GBP","PBM","NQmain","IE00B3QW5Z07.USD","NVIW.SI","PSQ","NDAQ","MRC","QID","QLD","IE00BKPKM429.USD","TQQQ","BK4104","SQQQ"],"gpt_icon":1},{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=fundamental","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SEEL","OPTHF","PHRRF","BETRF","QNTM","MYCOF","IXHL","SPRC","BK4547","FLHLF","MDXXF","BK4139","BK4539","ATAI","RLMD","PBM","CMPS","NUMIF","BK4007","MIRA","RVVTF","GHRS","CMND","ALID","AGNPF","SILO","KTTA","ENTBF","DRUG","CYBN","PSYGF","MNMD","SNPX","BK4168","NRXP","BK4202"],"gpt_icon":0},{"id":"2521613253","title":"UnitedHealth's Optum Rx & EPN Team Up for Fairer Pharmacy Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2521613253","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521613253?lang=en_us&edition=fundamental","pubTime":"2025-03-22 00:55","pubTimestamp":1742576100,"startTime":"0","endTime":"0","summary":"UnitedHealth Group’s UNH Optum Rx recently announced a major step toward modernizing pharmacy payments, a decision that could strengthen its market position and financial outlook. By adopting a cost-based reimbursement model, Optum Rx aims to provide fairer payments to pharmacies while improving medication access and affordability for consumers. Epic Pharmacy Network has partnered with Optum Rx to implement this model.This shift is especially beneficial for independent and community pharmacies, which have long struggled with rising drug prices and unpredictable reimbursement rates. With over 24,000 independent pharmacies in its network, Optum Rx’s new model ensures financial stability for these businesses, helping them maintain better medication stocks and improve patient care.This move bodes well for UNH as it is expected to increase pharmacy participation in Optum Rx’s network, enhancing service delivery and consumer satisfaction. By eliminating retroactive payment adjustments and re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/unitedhealths-optum-rx-epn-team-165500343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TISI","LU0456855351.SGD","IE00B894F039.SGD","LU0114720955.EUR","IE00B19Z8X17.USD","LU1323610961.USD","SG9999017495.SGD","MD","ENSG","IE00B2B36J28.USD","LU0238689110.USD","LU0029864427.USD","LU0708994859.HKD","LU1989771016.USD","IE00B4JS1V06.HKD","LU1064131342.USD","LU2244417387.USD","BK4588","LU0011850046.USD","SGXZ81514606.USD","IE0004445015.USD","LU0965509283.SGD","LU0661504455.SGD","LU2211815571.USD","LU1066051811.HKD","LU2362541273.HKD","BK4585","LU1267930573.SGD","LU2552382058.USD","LU2125154778.USD","LU0128525929.USD","LU2461242641.AUD","IE00B19Z3B42.SGD","LU1674673691.USD","SG9999002224.SGD","LU1037948541.HKD","LU0965509101.SGD","LU0823416689.USD","SGXZ51526630.SGD","PBM","UNH","LU1732800096.USD","IE00BZ9MQY76.HKD","LU0965508806.USD","IE00B19Z8W00.USD","ADUS","LU1854103824.USD","LU1084165304.USD","LU0949170772.SGD","LU2491050154.USD"],"gpt_icon":0},{"id":"2520870879","title":"UnitedHealth Group (UNH): The Best Diabetes Stock to Buy According to Billionaires","url":"https://stock-news.laohu8.com/highlight/detail?id=2520870879","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520870879?lang=en_us&edition=fundamental","pubTime":"2025-03-19 01:36","pubTimestamp":1742319384,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where UnitedHealth Group Incorporated  stands against other best diabetes stocks to buy according to billionaires.The Growing Market and Innovation in Continuous Glucose Monitoring  Technology. The GlobalData marketed products database shows that there are currently 97 products in the CGM category. Most of these devices are standard CGMs, with only a few being implanted sensors. 133 products are either approved or in the development stage, according to the GlobalData pipeline products database. The research indicates that this market niche is expanding quickly and is a hub for innovative new technologies like implantable CGMs.Twelve percent of adult Americans report having taken a GLP-1 drug at some point, according to the most recent KFF Health Tracking poll. In the previous fi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/unitedhealth-group-unh-best-diabetes-173624813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAGR","LU2552382132.HKD","LU0211326839.USD","LU0345770993.USD","LU0345770308.USD","LU0912757837.SGD","LU0107464264.USD","LU1057294990.SGD","BK4585","BK4139","LU2111349929.HKD","IE00B19Z8X17.USD","LU1064131342.USD","LU2360032135.SGD","LU0354030511.USD","LU0289739699.SGD","LU0689472784.USD","LU0128525929.USD","LU0708995401.HKD","LU0661504455.SGD","LU0528227936.USD","IE00B1XK9C88.USD","LU0353189680.USD","LU0187121727.USD","LU0820561909.HKD","LU1291159041.SGD","BK4154","LU0496365809.HKD","LU2264538146.SGD","LU0557290698.USD","LU0094547139.USD","LU0320765059.SGD","SG9999002224.SGD","LU0545039389.USD","LU0965509101.SGD","BK4532","LU0097036916.USD","LU1720051108.HKD","LU1061106388.HKD","LU0976567544.SGD","LU0342679015.USD","LU1983299246.USD","LU2087625088.SGD","SGXZ31699556.SGD","PBM","UNH","LU2242649171.HKD","LU2552382058.USD","LU0198837287.USD"],"gpt_icon":0},{"id":"2520676324","title":"Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein","url":"https://stock-news.laohu8.com/highlight/detail?id=2520676324","media":"Newsfile","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520676324?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:30","pubTimestamp":1742301000,"startTime":"0","endTime":"0","summary":"Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies. \"Dr. Stein brings decades of diverse clinical and scientific experience in the area of psychopharmacology and psychotherapy trials, and I could not be more excited to welcome him to our SAB,\" stated Dr. Neil Maresky, M.B.,B.Ch., Chief Executive Officer of Psyence Biomed. \"While we continue in our Phase IIb clinical trial of psilocybin as a potential treatment for Adjustment Disorder in Palliative Care, we will also be advancing plans for our second development indication in Alcohol Use Disorder. With the objective guidance from our world-class SAB, I believe we are well positioned to introduce an entirely new class of psilocybin-based therapeutics to address significant unmet needs in mental health and addiction.\". \"Psychedelic therapies hold promise in psychiatry across a number of indications,\" stated Dr. Stein. \"I am excited to join Psyence Biomed's SAB at this crucial time fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psyence-biomed-further-strengthens-scientific-123000681.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psyence-biomed-further-strengthens-scientific-123000681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBM","TQQQ","MRC","NVIW.SI","NQmain","TSYW.SI","USJW.SI","SQQQ","BK4139","QID","PBMWW","MNQmain","USAW.SI",".IXIC","QLD","BK4104","PSQ"],"gpt_icon":1},{"id":"2520152115","title":"GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement","url":"https://stock-news.laohu8.com/highlight/detail?id=2520152115","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520152115?lang=en_us&edition=fundamental","pubTime":"2025-03-17 21:00","pubTimestamp":1742216400,"startTime":"0","endTime":"0","summary":"Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx. Aaron will be responsible for the management and financial performance of GoodRx’s Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager , employer, and manufacturer partners. He will also play a critical role in shaping GoodRx’s long-term growth strategy and serve as a strategic advisor to the CEO and President, helping to guide the company’s broader vision and business priorities.GoodRx is the leading platform for medication savings in the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/goodrx-appoints-aaron-crittenden-president-130000524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBM","GDRX","BK4139","BK4167"],"gpt_icon":1},{"id":"2519638156","title":"Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519638156","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519638156?lang=en_us&edition=fundamental","pubTime":"2025-03-14 23:40","pubTimestamp":1741966809,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement.Discover stocks' market position with detailed  competitor analyses.MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals  announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company’s pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects.“The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,” stated Erez Aminov, CEO . “By adv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENVB","RLMD","MYCOF","BK4202","SILO","NUMIF","SNPX","DRUG","FLHLF","MNMD","BK4168","ATAI","RVVTF","KTTA","BK4539","BETRF","AGNPF","CMND","PBM","NRXP","CYBN","CMPS","SPRC","ENTBF","QNTM","SEEL","BK4139","PSYGF","BK4007","GHRS","IXHL","MDXXF","PHRRF","ALID","OPTHF","BK4547","MIRA"],"gpt_icon":0},{"id":"2518896167","title":"Is CVS Health (CVS) the Best Stock to Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2518896167","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518896167?lang=en_us&edition=fundamental","pubTime":"2025-03-11 05:07","pubTimestamp":1741640828,"startTime":"0","endTime":"0","summary":"We recently published a list of Stocks On the Rise: 10 Best Stocks to Buy Right Now. In this article, we are going to take a look at where CVS Health Corporation  stands against other best stocks to buy right now.As per Merrill Lynch, 2025 has not shown much movement. Between the US tariffs and trade wars, geopolitical scenarios, and more, investors continue to be surrounded by attention-grabbing headlines. The firm believes that investors are required to stay focused on numerous key trends that continue to emerge beneath the surface, such as a rebound in the global economic activity, demonstrating signs of a manufacturing recovery. The US continues to be aided by a strong consumer and healthy labor market with double-digit US earnings growth and the unfolding of market rotation. Elsewhere, China has been making efforts to revive its business confidence and consumption. Also, certain parts of Europe have been experiencing expansion mode.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvs-health-cvs-best-stock-210708443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2063271972.USD","LU2361044865.SGD","IE0004445015.USD","LU0708995401.HKD","LU2764263039.SGD","LU0072461881.USD","LU2361045086.USD","LU0070302665.USD","LU1316542783.SGD","LU2456880835.USD","LU0170899867.USD","LU1691799644.USD","SG9999001077.SGD","LU2236285917.USD","LU2087625088.SGD","BK4535","LU1814569148.SGD","LU1551013425.SGD","LU0823421416.USD","IE00BYQQ9H92.USD","LU2720916845.USD","LU1366192091.USD","LU1084165304.USD","LU0061474960.USD","LU1852331112.SGD","LU0006306889.USD","IE00BWXC8680.SGD","LU1917777945.USD","LU2077746001.SGD","LU2756315318.SGD","LU0820562030.AUD","SG9999001424.SGD","LU0689472784.USD","MA","IE0009356076.USD","LU1551013342.USD","IE00BZ1G4Q59.USD","LU0061475181.USD","LU0823434583.USD","LU1989764748.USD","LU2461242641.AUD","LU0056508442.USD","LU1670627923.USD","PBM","CVS","LU0345770308.USD","LU2108987350.USD","LU2764263203.CNY","LU0320765059.SGD","SGXZ81514606.USD"],"gpt_icon":0},{"id":"2518279456","title":"Psyence Group's Nasdaq-Listed Associate, Psyence Biomedical, Names Albert P. Garcia-Romeu, Ph.d. as Chair of Its Newly Created Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2518279456","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518279456?lang=en_us&edition=fundamental","pubTime":"2025-03-10 23:18","pubTimestamp":1741619919,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUA7TXPGZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2518633271","title":"Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2518633271","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518633271?lang=en_us&edition=fundamental","pubTime":"2025-03-10 23:18","pubTimestamp":1741619880,"startTime":"0","endTime":"0","summary":"Psyence Group settles Debt for SharesTORONTO, March  10, 2025  (GLOBE NEWSWIRE) -- Psyence Group Inc (\"Psyence Group\" or the \"Company\") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039935/0/en/Psyence-Group-s-NASDAQ-Listed-Associate-Psyence-Biomedical-names-Albert-P-Garcia-Romeu-Ph-D-as-Chair-of-its-Newly-Created-Scientific-Advisory-Board.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USJW.SI","BK4585","IE00B3QW5Z07.USD","QID","PSQ","NVIW.SI","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP","QLD","LU2210149790.SGD","NQmain","IE00BGHQF748.EUR","IE00BKPKM429.USD",".IXIC","TSYW.SI","BK4588","MNQmain","TQQQ","USAW.SI","BK4139","PBM","BK4112","LU2095319765.USD","SQQQ"],"gpt_icon":1},{"id":"2518237654","title":"Is CVS Health Corporation (CVS) the Top Health Insurance Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2518237654","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518237654?lang=en_us&edition=fundamental","pubTime":"2025-03-10 08:10","pubTimestamp":1741565402,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the Top 10 Health Insurance Stocks To Buy.In this article, we are going to take a look at where CVS Health Corporation  stands against the other health insurance stocks.The health insurance industry is constantly changing, driven by a movement towards consumer-driven healthcare, in which people actively control their own health and healthcare costs. In that sense, Fortune Business Insights projects that the global healthcare insurance market is estimated to be worth $2.14 trillion in 2024 and will grow from $2.32 trillion in 2025 to roughly $4.45 trillion by 2032, reflecting a 9.7% CAGR over the forecast period.According to McKinsey, health insurers might benefit significantly from completely incorporating AI and automation into their business operations. The firm believes that for every $10 billion in revenue, insurers could save $150 million to $300 million in administrative costs and $380 million to $970 million in medical expenses. In addition, these ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvs-health-corporation-cvs-top-001002322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1623119135.USD","LU2213496289.HKD","LU2456880835.USD","LU0316494557.USD","LU0708995401.HKD","LU1718418525.SGD","LU0964807845.USD","LU0096362180.USD","LU1814569148.SGD","IE00BYQQ9H92.USD","LU1280957306.USD","LU0820561818.USD","LU0162691827.USD","LU1145028129.USD","LU0689472784.USD","LU0868494708.USD","IE0004445239.USD","PBM","LU0557290698.USD","LU0942090050.USD","LU2756315318.SGD","CVS","LU1084165304.USD","LU0985320562.USD","LU2462157665.USD","BK4504","ACA","LU0256863811.USD","LU0320765489.SGD","LU2108987350.USD","LU0971096721.USD","LU1551013425.SGD","LU1852331112.SGD","LU0006306889.USD","IE00BFXG0V08.USD","IE00BZ1G4Q59.USD","LU2403377893.USD","LU1917777945.USD","LU1670627923.USD","MA","LU1119994496.HKD","LU0786609619.USD","LU0390134368.USD","LU2420271590.USD","BK4566","LU0234572021.USD","BK4534","LU1974910355.USD","IE0004445015.USD","GB00BDT5M118.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":113,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-26","symbol":"PBM","defaultRemindTime":1732631400000,"type":"split","dateTimestamp":1732597200000,"forFactor":75,"toFactor":1,"ratio":75}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBM\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PBM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PBM","date":"2025-04-16","current":-0.046939,"percent":0.741135,"low":-8.987173,"twenty":-3.473698,"median":-0.133745,"eighty":-0.039953,"high":-0.010313,"avg":-1.482032,"sd":1.933713,"marketCap":2187001},"quantilePoints":[{"date":"2024-02-09","current":-4.032357,"twenty":-6.238869,"median":-6.072412,"eighty":-4.789887,"marketCap":12687649},{"date":"2024-02-16","current":-2.839339,"twenty":-6.098548,"median":-3.798256,"eighty":-3.119893,"marketCap":8908805},{"date":"2024-02-23","current":-2.317077,"twenty":-5.416526,"median":-3.308726,"eighty":-2.830575,"marketCap":7275145},{"date":"2024-03-01","current":-2.358335,"twenty":-4.411122,"median":-2.857169,"eighty":-2.443954,"marketCap":7364862},{"date":"2024-03-08","current":-5.40272,"twenty":-4.595223,"median":-2.890292,"eighty":-2.448252,"marketCap":17006136},{"date":"2024-03-15","current":-6.789855,"twenty":-5.670597,"median":-3.448439,"eighty":-2.49853,"marketCap":21291147},{"date":"2024-03-22","current":-4.959176,"twenty":-5.522615,"median":-3.851628,"eighty":-2.531651,"marketCap":15533164},{"date":"2024-03-28","current":-5.045126,"twenty":-5.473209,"median":-4.390178,"eighty":-2.58397,"marketCap":15800977},{"date":"2024-04-05","current":-4.43423,"twenty":-5.384879,"median":-4.562142,"eighty":-2.723572,"marketCap":13926285},{"date":"2024-04-12","current":-3.616183,"twenty":-5.308825,"median":-4.386712,"eighty":-2.826193,"marketCap":11169148},{"date":"2024-04-19","current":-2.969424,"twenty":-5.158983,"median":-4.227564,"eighty":-2.846471,"marketCap":9153854},{"date":"2024-04-26","current":-3.634228,"twenty":-5.044947,"median":-3.989124,"eighty":-2.883667,"marketCap":11244136},{"date":"2024-05-03","current":-5.498334,"twenty":-5.135216,"median":-4.022166,"eighty":-2.931227,"marketCap":17006136},{"date":"2024-05-10","current":-4.755664,"twenty":-5.044947,"median":-4.198236,"eighty":-2.950931,"marketCap":14729724},{"date":"2024-05-17","current":-3.914422,"twenty":-5.029183,"median":-4.161003,"eighty":-2.965515,"marketCap":12185499},{"date":"2024-05-24","current":-3.576034,"twenty":-4.995271,"median":-3.989124,"eighty":-2.992841,"marketCap":11063362},{"date":"2024-05-31","current":-3.172702,"twenty":-4.97525,"median":-3.912167,"eighty":-3.056175,"marketCap":9842134},{"date":"2024-06-07","current":-3.011838,"twenty":-4.945403,"median":-3.739796,"eighty":-3.056175,"marketCap":9326593},{"date":"2024-06-14","current":-2.737094,"twenty":-4.890312,"median":-3.704137,"eighty":-2.962909,"marketCap":8436115},{"date":"2024-06-21","current":-2.59705,"twenty":-4.889793,"median":-3.670898,"eighty":-2.901711,"marketCap":8034395},{"date":"2024-06-28","current":-1.423571,"twenty":-4.880728,"median":-3.666452,"eighty":-2.842905,"marketCap":4405526},{"date":"2024-07-05","current":-1.29697,"twenty":-4.844987,"median":-3.634228,"eighty":-2.817429,"marketCap":4038622},{"date":"2024-07-12","current":-1.419038,"twenty":-4.808586,"median":-3.573896,"eighty":-2.622548,"marketCap":4414900},{"date":"2024-07-15","current":-1.341218,"twenty":-4.798002,"median":-3.571758,"eighty":-2.605002,"marketCap":4160477},{"date":"2024-08-02","current":-2.495253,"twenty":-4.787417,"median":-3.567957,"eighty":-2.598476,"marketCap":7638460},{"date":"2024-08-09","current":-2.374588,"twenty":-4.74111,"median":-3.476328,"eighty":-2.509232,"marketCap":7322012},{"date":"2024-08-16","current":-0.189652,"twenty":-4.701156,"median":-3.451094,"eighty":-2.420293,"marketCap":7080967},{"date":"2024-08-23","current":-0.185364,"twenty":-4.666284,"median":-3.259617,"eighty":-2.320199,"marketCap":6969168},{"date":"2024-08-30","current":-0.135409,"twenty":-4.625942,"median":-3.217804,"eighty":-1.734415,"marketCap":6927407},{"date":"2024-09-06","current":-0.075064,"twenty":-4.578612,"median":-3.173134,"eighty":-1.374452,"marketCap":3840211},{"date":"2024-09-13","current":-0.0531,"twenty":-4.542825,"median":-3.169013,"eighty":-1.297908,"marketCap":2716532},{"date":"2024-09-20","current":-0.041677,"twenty":-4.46068,"median":-2.990631,"eighty":-0.405342,"marketCap":2132152},{"date":"2024-09-27","current":-0.035704,"twenty":-4.439776,"median":-2.942945,"eighty":-0.186722,"marketCap":1826604},{"date":"2024-10-04","current":-0.033616,"twenty":-4.415223,"median":-2.885007,"eighty":-0.176524,"marketCap":1719746},{"date":"2024-10-11","current":-0.029797,"twenty":-4.335882,"median":-2.827764,"eighty":-0.136917,"marketCap":1524396},{"date":"2024-10-18","current":-0.037238,"twenty":-4.316906,"median":-2.814639,"eighty":-0.115509,"marketCap":1905078},{"date":"2024-10-25","current":-0.030678,"twenty":-4.280698,"median":-2.661,"eighty":-0.061781,"marketCap":1569477},{"date":"2024-10-31","current":-0.030678,"twenty":-4.227564,"median":-2.600616,"eighty":-0.0531,"marketCap":1569477},{"date":"2024-11-08","current":-0.025359,"twenty":-4.168908,"median":-2.560506,"eighty":-0.041677,"marketCap":1297323},{"date":"2024-11-15","current":-0.017624,"twenty":-4.161003,"median":-2.495253,"eighty":-0.039164,"marketCap":901614},{"date":"2024-11-22","current":-0.015339,"twenty":-4.032357,"median":-2.443919,"eighty":-0.0359,"marketCap":784738},{"date":"2024-11-29","current":-0.015056,"twenty":-4.024204,"median":-2.389624,"eighty":-0.035548,"marketCap":770265},{"date":"2024-12-06","current":-0.011488,"twenty":-3.969299,"median":-2.324881,"eighty":-0.03483,"marketCap":587716},{"date":"2024-12-13","current":-0.039719,"twenty":-3.922754,"median":-2.279872,"eighty":-0.03483,"marketCap":2031982},{"date":"2024-12-20","current":-0.047896,"twenty":-3.910815,"median":-1.423571,"eighty":-0.034491,"marketCap":2450332},{"date":"2024-12-27","current":-0.160105,"twenty":-3.826552,"median":-1.380322,"eighty":-0.034771,"marketCap":8190835},{"date":"2025-01-03","current":-0.139339,"twenty":-3.758505,"median":-1.341218,"eighty":-0.034902,"marketCap":7128426},{"date":"2025-01-10","current":-0.109104,"twenty":-3.738121,"median":-1.298666,"eighty":-0.034986,"marketCap":5581651},{"date":"2025-01-17","current":-0.104953,"twenty":-3.725963,"median":-1.286602,"eighty":-0.035261,"marketCap":5369305},{"date":"2025-01-24","current":-0.101395,"twenty":-3.704137,"median":-0.723378,"eighty":-0.035313,"marketCap":5187295},{"date":"2025-01-31","current":-0.153931,"twenty":-3.696057,"median":-0.190404,"eighty":-0.035607,"marketCap":7171947},{"date":"2025-02-07","current":-0.131126,"twenty":-3.670898,"median":-0.185677,"eighty":-0.035672,"marketCap":6109436},{"date":"2025-02-14","current":-0.121624,"twenty":-3.666452,"median":-0.178318,"eighty":-0.035704,"marketCap":5666723},{"date":"2025-02-21","current":-0.130176,"twenty":-3.664547,"median":-0.173585,"eighty":-0.035861,"marketCap":6065165},{"date":"2025-02-28","current":-0.117824,"twenty":-3.640197,"median":-0.162785,"eighty":-0.035996,"marketCap":5489638},{"date":"2025-03-07","current":-0.085527,"twenty":-3.619792,"median":-0.159632,"eighty":-0.03602,"marketCap":3984857},{"date":"2025-03-14","current":-0.072186,"twenty":-3.584064,"median":-0.152664,"eighty":-0.036994,"marketCap":3363289},{"date":"2025-03-21","current":-0.063663,"twenty":-3.572613,"median":-0.146804,"eighty":-0.03763,"marketCap":2966175},{"date":"2025-03-28","current":-0.062237,"twenty":-3.565676,"median":-0.142018,"eighty":-0.03885,"marketCap":2899768},{"date":"2025-04-04","current":-0.055206,"twenty":-3.522789,"median":-0.138728,"eighty":-0.039157,"marketCap":2572161},{"date":"2025-04-11","current":-0.042958,"twenty":-3.483552,"median":-0.135123,"eighty":-0.039608,"marketCap":2001504},{"date":"2025-04-16","current":-0.046939,"twenty":-3.473698,"median":-0.133745,"eighty":-0.039953,"marketCap":2187001}],"updateTime":1744953773794}}}